Vaccine Formulation Scientists are experts responsible for developing and refining the composition of vaccines to ensure they are both effective and safe for public use. They work on formulating vaccines by selecting the appropriate antigens, stabilizers, and adjuvants that will trigger a robust immune response while maintaining the stability and integrity of the vaccine during storage and distribution. These scientists use cutting-edge technologies and knowledge of immunology to design formulations that not only induce immunity but also remain stable under various environmental conditions. Their work is essential in creating vaccines that are scalable, affordable, and suitable for global vaccination efforts, especially in the face of emerging infectious diseases.
Vaccine formulation scientists also collaborate with regulatory bodies to ensure that vaccines meet safety and efficacy standards before they are approved for public use. They are involved in pre-clinical and clinical trials, analyzing data to make adjustments to formulations as needed. Their role is crucial in the rapid development of vaccines during outbreaks, such as the COVID-19 pandemic, where quick yet safe formulations were necessary to curb the spread of the virus. Through their expertise, vaccine formulation scientists help make life-saving vaccines accessible to millions of people worldwide. As science advances, their work remains at the forefront of global health innovation.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States